Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina.

Pharmacoecon Open · 2024 · PMC11252110 · PMID 38831188

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Conclusion The introduction of olaparib for the treatment of BRCAm women with PSROC has a high budget impact for all three health systems in Argentina, with an increasing trend during the 5-year time horizon.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.